Related references
Note: Only part of the references are listed.Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?
Ahmed El-Zawahry et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2020)
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo -controlled Study (MATCH)
Hidehiro Kakizaki et al.
EUROPEAN UROLOGY FOCUS (2020)
Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
Howard B. Goldman et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
Updating the evidence on drugs to treat overactive bladder: a systematic review
Frances C. Hsu et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2019)
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
David Staskin et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2018)
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
Con Kelleher et al.
EUROPEAN UROLOGY (2018)
6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE
Paul Abrams et al.
NEUROUROLOGY AND URODYNAMICS (2018)
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder
Chung-Cheng Wang et al.
LUTS-LOWER URINARY TRACT SYMPTOMS (2017)
Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder
Naoki Wada et al.
LUTS-LOWER URINARY TRACT SYMPTOMS (2016)
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females
Yuki Nomura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2016)
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment
E. Ann Gormley et al.
JOURNAL OF UROLOGY (2015)
A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction
Koji Ichihara et al.
JOURNAL OF UROLOGY (2015)
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
Walter Krauwinkel et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2014)
Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men
Marcel van Gelderen et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)
Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder
Michael B. Chancellor et al.
CLINICAL THERAPEUTICS (2013)
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
V. W. Nitti et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Mirabegron: a review of recent data and its prospects in the management of overactive bladder
Emilio Sacco et al.
THERAPEUTIC ADVANCES IN UROLOGY (2012)
Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature
C. C. Sexton et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations
Gabriela Franco-Salinas et al.
CLINICAL PHARMACOKINETICS (2010)
The influence of Alpha1-Adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract
Marcello Trevisani et al.
EUROPEAN UROLOGY (2007)
Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats
Osamu Yokoyama et al.
JOURNAL OF UROLOGY (2007)
Treatment of overactive bladder in the aging population: focus on darifenacin
Swati Jha et al.
CLINICAL INTERVENTIONS IN AGING (2006)
The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®)
MC Michel et al.
EUROPEAN UROLOGY SUPPLEMENTS (2005)
Prevalence and burden of overactive bladder in the United States
WF Stewart et al.
WORLD JOURNAL OF UROLOGY (2002)
How widespread are the symptoms of an overactive bladder and how are they managed?: A population-based prevalence study
I Milsom et al.
BJU INTERNATIONAL (2001)
Share Paper
